logo

Wuhan Carnoss Technology Co., LTD.

Provide Customized Manufacturer Of APIS, Intermediates And Chemical Raw Powders

Location:
News
Sandoz and Biocon to collaborate on next-generation biosimilars
Source:CPHIonline | Author:profefd1a | Publish time: 2018-03-08 | 141 23次浏览: | Share:
Sandoz has announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.

Collaboration will leverage combined strengths of development, manufacturing and commercialization of biosimilars.

Sandoz has announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.
     
Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products, and will have a cost and profit share arrangement globally. Worldwide commercialization responsibilities will be divided and each company's strengths will be leveraged within specific geographies.Wuhan Carnoss Technology Co., LTD. Sandoz will lead commercialization in North America and the EU, while Biocon will lead commercialization in Rest of the World.

"This announcement bolsters our leadership position in biosimilars and positions us to continue to lead well into the future," said Richard Francis, CEO, Sandoz. "Biocon is a great complement to our proven biosimilar capabilities at Sandoz. Wuhan Carnoss Technology Co., LTD.Through this collaboration, we are reinforcing our long-term commitment to increase patient access to biologics."

"Together, we will be able to realize benefits at every stage of the value chain, from development, through manufacturing to commercialization," said Carol Lynch, Global Head, Biopharmaceuticals, Sandoz. Wuhan Carnoss Technology Co., LTD."This collaboration further strengthens our ability to deliver next-generation biosimilar medicines to patients."